Andere talen Nexalin Technology, Inc.

Aandelen

NXL

US65345B2016

Beurs gesloten - Nasdaq Andere beurzen 22:00:00 24-05-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
1,01 ^USD	-4,72%		-22,90%	+149,51%

10/05	Nexalin Technology, Inc. rapporteert resultaten voor het eerste kwartaal eindigend op 31 maart 2024	CI
25/04	Nexalin Technology voldoet weer aan Nasdaq noteringvereiste	MT

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Nexalin America Selected to Join the National Traumatic Brain Injury Registry Coalition to Propel TBI Awareness and Research Efforts	22/05
Nexalin Technology, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	10/05
Join Nexalin Technology’s Exclusive Live Investor Webinar and Q&A Session on May 23	09/05
Nexalin Technology Regains Compliance With Nasdaq Listing Requirement	25/04
Nexalin Technology Regains Compliance with Nasdaq Continued Listing Requirements	25/04
Nexalin Technology : unveils positive results of clinical study for Gen-2 tACS device	18/04
Nexalin Technology Files $5.6 Million Shelf Registration	16/04
Nexalin Technology CEO Provides Letter to Shareholders	10/04
Nexalin Technology Accelerates Manufacturing of its HALO™ Clarity Following Successful Usability, Feasibility, and Electrical Testing	09/04
Nexalin Technology Accelerates Manufacturing of Its HALO? Clarity Following Successful Usability, Feasibility, and Electrical Testing	09/04
Nexalin Technology Awarded Key Patent Related to its Gen-3 HALO Clarity™, a Non-Invasive, Frequency-Based Deep-Brain Stimulation Device	04/04
Nexalin Technology unveils positive results of clinical study for Gen-2 tACS device	04/04
Nexalin Technology Announces the Appointment of Government Affairs Veteran William A. Hudson, Jr. to Military & Government Advisory Board	02/04
Nexalin Technology, Inc. Announces the Appointment of William A. Hudson, Jr. to Military & Government Advisory Board	02/04
Top Midday Gainers	28/03
Nexalin Technology Announces Positive Results of Clinical Study Validating its Gen-2 tACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	28/03
Nexalin Technology, Inc. Announces Positive Results of Clinical Study Validating its Gen-2 TACS Device for Reducing Pain Among Veterans with Mild Traumatic Brain Injury at University of California, San Diego	28/03
Nexalin Technology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27/03
Nexalin Technology Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman Dedicated to Nexalin’s Technology	14/03
Nexalin Technology, Inc. Commences Sales of Gen-2 Neurostimulation Device to New Mental Health Center in Oman	14/03

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Nexalin Technology, Inc.

Aandelen

NXL

US65345B2016

Andere talen

Filters